Author:
Ferensztajn-Rochowiak Ewa,Lewitzka Ute,Chłopocka-Woźniak Maria,Rybakowski Janusz K.
Abstract
Abstract
Background
The phenomenon of preventing the recurrences of mood disorders by the long-term lithium administration was discovered sixty years ago. Such a property of lithium has been unequivocally confirmed in subsequent years, and the procedure makes nowadays the gold standard for the pharmacological prophylaxis of bipolar disorder (BD). The efficacy of lithium prophylaxis surpasses other mood stabilizers, and the drug has the longest record as far as the duration of its administration is concerned. The continuation of lithium administration in case of good response could be a lifetime and last for several decades. The stability of lithium prophylactic efficacy in most patients is pretty steady. However, resuming lithium after its discontinuation may, in some patients, be less efficient.
Main body
In the article, the clinical and biological factors connected with the prophylactic efficacy of long-term lithium administration are listed. Next, the adverse and beneficial side effects of such longitudinal treatment are presented. The main problems of long-term lithium therapy, which could make an obstacle to lithium continuation, are connected with lithium’s adverse effects on the kidney and, to lesser extent, on thyroid and parathyroid functions. In the paper, the management of these adversities is proposed. Finally, the case reports of three patients who have completed 50 years of lithium therapy are described.
Conclusions
The authors of the paper reckon that in the case of good response, lithium can be given indefinitely. Given the appropriate candidates for such therapy and successful management of the adverse effects, ultra-long term lithium therapy is possible and beneficial for such patients.
Funder
Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
Publisher
Springer Science and Business Media LLC
Reference112 articles.
1. Abramowicz M, Chlopocka-Wozniak M, Kraszewska A, Czekalski S, Rybakowski J. Hypercalcaemia and hyperparathyroidism in bipolar patients on long-term lithium treatment (in Polish). Pharmacother Psychiatry Neurol. 2014;30:21–7.
2. Abramowicz M, Permoda-Osip A, Nowak B, Olejniczak P, Rybakowski JK. Five-year observation of chronic renal insufficiency during lithium treatment a case study of four patients. Pharmacother Psychiatry Neurol. 2017;33:169–79. https://doi.org/10.7393/fpn.2017.12.006.
3. Aiff H, Attman PO, Aurell M, Bendz H, Schön S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24:540–4.
4. Altamura AC, Mundo E, Dell’Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: a 4-year follow-up naturalistic study. J Affect Disord. 2008;110:135–41.
5. Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Cearns M, et al. Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Mol Psychiatry. 2021;26:2457–70.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献